Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement

References

• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
   PubMedGoogle Scholar
• Johannson KA, Kolb M, Fell CD, Assayag D, Fisher J, Churg A. Evaluation of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(3):133–141.
   Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.
   PubMed Web of Science ®Google Scholar
• Gupta S, Bhattacharyya OK, Brouwers MC, et al. Canadian Thoracic Society: Presenting a New Process for Clinical Practice Guideline Production. Can Respir J. 2009;16(6):e62.
   Google Scholar
• Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839–EE42.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day BM, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–761.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–2666.
   PubMed Web of Science ®Google Scholar
• Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619–625.
   PubMed Web of Science ®Google Scholar
• Chartrand S, Fischer A. Management of connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am. 2015;41(2):279–294.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom K, King TJ, Lasky J, Martinez F. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Camp PG, Hernandez P, Bourbeau J, et al. Pulmonary rehabilitation in Canada: a report from the Canadian Thoracic Society COPD Clinical Assembly. Can Respir J. 2015;22(3):147–152.
   PubMed Web of Science ®Google Scholar
• Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–554.
   PubMed Web of Science ®Google Scholar
• Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–399.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014;108(1):203–210.
   PubMed Web of Science ®Google Scholar
• Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. 2010;5(1):31–37.
   PubMed Web of Science ®Google Scholar
• Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2012;106(3):429–435.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135(2):442–447.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56(6):783–789.
   Google Scholar
• Global Strategy for Diagnosis M, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015, 2015.
   Google Scholar
• Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration. 2011;81(3):196–205.
   PubMed Web of Science ®Google Scholar
• Johnson-Warrington V, Williams J, Bankart J, Steiner M, Morgan M, Singh S. Pulmonary rehabilitation and interstitial lung disease: aiding the referral decision. J Cardiopulm Rehabil Prev. 2013;33(3):189–195.
   Google Scholar
• Spielmanns M, Gloeckl R, Schmoor C, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: A retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med. 2016;113:8–14.
   PubMed Web of Science ®Google Scholar
• Du Plessis JP, Fernandes S, Jamal R, et al. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology 2017;23(4):392–398.
   Google Scholar
• Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014;2014(10):Cd006322.
   Google Scholar
• Rammaert B, Leroy S, Cavestri B, Wallaert B, Grosbois JM. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. Rev Mal Respir. 2011;28(7):e52–e57.
   Google Scholar
• Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42(2):444–453.
   PubMed Web of Science ®Google Scholar
• Morisset J, Dube BP, Garvey C, et al. The unmet educational needs of patients with interstitial lung disease. Setting the stage for tailored pulmonary rehabilitation. Annals Ats. 2016;13(7):1026–1033.
   Google Scholar
• Holland AE, Fiore JF, Jr., Goh N, et al. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis. 2015;12(2):93–101.
   PubMed Web of Science ®Google Scholar
• Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143(2):219–225.
   Google Scholar
• Agusti AG, Roca J, Rodriguez-Roisin R, Xaubet A, Agusti-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J. 1988;1(6):510–516.
   Google Scholar
• Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest. 1984;85(1):69–74.
   Google Scholar
• Sharp C, Adamali H, Millar AB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2016;7:Cd011716.
   PubMedGoogle Scholar
• Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93(3):391–398.
   PubMed Web of Science ®Google Scholar
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681–686.
   PubMed Web of Science ®Google Scholar
• Morrison DA, Stovall JR. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992;102(2):542–550.
   Google Scholar
• Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med. 2003;168(9):1034–1042.
   PubMed Web of Science ®Google Scholar
• Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gené RJ. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. Chest. 2001;120(2):437–443.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med. 1997;155(2):530–535.
   PubMed Web of Science ®Google Scholar
• Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000;161(4):1172–1178.
   Google Scholar
• Bye PT, Anderson SD, Woolcock AJ, Young IH, Alison JA. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am Rev Respir Dis. 1982;126(6):1005–1012.
   PubMed Web of Science ®Google Scholar
• Harris-Eze AO, Sridhar G, Clemens RE, Gallagher CG, Marciniuk DD. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1616–1622.
   PubMed Web of Science ®Google Scholar
• Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J. 2011;38(4):987–990.
   PubMed Web of Science ®Google Scholar
• Albert RK, Au DH, Blackford AL, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617–1627.
   PubMed Web of Science ®Google Scholar
• Cao M, Wamboldt FS, Brown KK, et al. Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users. Multidiscip Respir Med. 2015;10(1):37.
   Google Scholar
• Lacasse Y, Bernard S, Maltais F. Eligibility for home oxygen programs and funding across Canada. Can Respir J. 2015;22(6):324–330.
   Google Scholar
• Johannson KA, Pendharkar SR, Mathison K, et al. Supplemental oxygen in interstitial lung disease: an art in need of science. Ann Am Thorac Soc. 2017;14(9):1373–1377.
   PubMed Web of Science ®Google Scholar
• Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax. 2015;70(Suppl 1):i1–43.
   PubMed Web of Science ®Google Scholar
• Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.
   PubMed Web of Science ®Google Scholar
• Canadian Organ Replacement Register, 2016.
   Google Scholar
• Organ Donation and Transplantation in Canada, 2016 System Progress Report Update. 2016:18.
   Google Scholar
• Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126(2):469–475.
   PubMed Web of Science ®Google Scholar
• Singer LG, Chowdhury NA, Faughnan ME, et al. Effects of recipient age and diagnosis on health-related quality-of-life benefit of lung transplantation. Am J Respir Crit Care Med. 2015;192(8):965–973.
   Google Scholar
• Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113–1130.
   PubMed Web of Science ®Google Scholar
• Gulack BC, Ganapathi AM, Speicher PJ, et al. What is the optimal transplant for older patients with idiopathic pulmonary fibrosis? Ann Thorac Surg. 2015;100(5):1826–1833.
   PubMed Web of Science ®Google Scholar
• Bernstein EJ, Peterson ER, Sell JL, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314–1322.
   PubMed Web of Science ®Google Scholar
• Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33(5):514–520.
   PubMed Web of Science ®Google Scholar
• Delanote I, Wuyts WA, Yserbyt J, Verbeken EK, Verleden GM, Vos R. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med. 2016;16(1):156.
   PubMed Web of Science ®Google Scholar
• Leuschner G, Stocker F, Veit T, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. 2017;37(2):268–274.
   Google Scholar
• Banga A, Sahoo D, Lane CR, Farver CF, Budev MM. Disease recurrence and acute cellular rejection episodes during the first year after lung transplantation among patients with sarcoidosis. Transplantation. 2015;99(9):1940–1945.
   Google Scholar
• Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE. Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: a review. Respirology. 2016;21(7):1173–1184.
   PubMed Web of Science ®Google Scholar
• The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report. J Heart Lung Transplant 2017;36(10):1037–1079.
   PubMedGoogle Scholar
• Sudore RL, Heyland DK, Lum HD, et al. Outcomes that define successful advance care planning: a Delphi panel consensus. J Pain Symptom Manage. 2017;55(2):245–255.e8.
   Google Scholar
• Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014;28(8):1000–1025.
   PubMed Web of Science ®Google Scholar
• Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. Ann Intern Med. 2010;153(4):256–261.
   PubMed Web of Science ®Google Scholar
• Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. Bmj. 2010;340:c1345.
   PubMed Web of Science ®Google Scholar
• Henrich NJ, Dodek PM, Alden L, Keenan SP, Reynolds S, Rodney P. Causes of moral distress in the intensive care unit: A qualitative study. J Crit Care. 2016;35:57–62.
   Google Scholar
• Bernacki RE, Block SD. Communication about serious illness care goals: a review and synthesis of best practices. JAMA Intern Med. 2014;174(12):1994–2003.
   PubMed Web of Science ®Google Scholar
• Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912–927.
   PubMed Web of Science ®Google Scholar
• Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015;147(2):423–429.
   PubMed Web of Science ®Google Scholar
• Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013;27(9):869–876.
   PubMed Web of Science ®Google Scholar
• Holland AE, Fiore JF, Jr., Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215–1221.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Yorke J, Sprunger DB, et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med. 2010;104(9):1350–1355.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage. 2012;43(4):771–782.
   PubMed Web of Science ®Google Scholar
• Chin C, Booth S. Managing breathlessness: a palliative care approach. Postgrad Med J. 2016;92(1089):393–400.
   Google Scholar
• Swan F, Booth S. The role of airflow for the relief of chronic refractory breathlessness. Curr Opin Support Palliat Care. 2015;9(3):206–211.
   PubMed Web of Science ®Google Scholar
• Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19(2):128–130.
   PubMed Web of Science ®Google Scholar
• Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev. 2002;2002(3):Cd002872.
   PubMedGoogle Scholar
• Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57(11):939–944.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Hui D, Currow DC. Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care. 2016;33(2):194–200.
   Google Scholar
• Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2010;2010(1):Cd007354.
   Google Scholar
• Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16(6):969–975.
   PubMed Web of Science ®Google Scholar
• Brown KK. Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):180s–185s.
   Google Scholar
• Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(8):995–1002.
   Google Scholar
• Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):412–416.
   PubMed Web of Science ®Google Scholar
• van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(4).
   Google Scholar
• Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. 2011;12(1):143.
   PubMedGoogle Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398–406.
   PubMed Web of Science ®Google Scholar
• Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–1589.
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Peccatori FA, Russell A-M. Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Eur Respir Rev. 2014;23(132):231–238.
   Google Scholar
• Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med. 2016;16(1):10.
   Google Scholar
• Bonella F, Wijsenbeek M, Molina-Molina M, et al. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597–606.
   PubMed Web of Science ®Google Scholar
• Fisher JH, O’Connor D, Flexman AM, Shapera S, Ryerson CJ. Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016;194(2):218–225.
   PubMed Web of Science ®Google Scholar
• Gadoury M-A, Schwartzman K, Rouleau M, et al. Self-management reduces both short- and long-term hospitalisation in COPD. Eur Respir J. 2005;26(5):853–857.
   Google Scholar